Medera Inc., a clinical-stage biopharmaceutical company, has announced the completion of patient dosing in its Phase 1/2a clinical trial for SRD-001, a gene therapy candidate designed to treat heart failure with reduced ejection fraction (HFrEF).
This condition is a prevalent form of heart disease, accounting for half of the estimated 64.3 million heart failure cases worldwide.
SRD-001 uses an adeno-associated virus (AAV) vector to deliver the SERCA2a gene directly to cardiac ventricular muscle cells, aiming to improve heart function and reduce symptoms of heart failure. The trial, known as MUSIC-HFrEF, has shown promising preliminary results, with clinically meaningful improvements in heart function and patient health observed at six and 12 months post-infusion.
Medera’s CEO and co-founder, Ronald Li, Ph.D., expressed enthusiasm about the results, noting that optimized dosages appear to be making a positive impact. The company is also moving forward with strategic partnerships, having entered into a definitive merger agreement with Keen Vision Acquisition Corporation in September 2024.
This milestone marks a significant step in the development of SRD-001, which could offer new hope for patients with advanced heart failure who currently have limited treatment options.
Related topics:
